Q-omics provides the consensus-scored GRIFIN profile across patient tissues and cancer cell-line models. GRIFIN expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GRIFIN is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GRIFIN RNA expression shows 15,276 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where GRIFIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIFIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIFIN survival associations across molecular data types. GRIFIN RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIFIN RNA expression–survival associations across cancer types. High GRIFIN expression shows unfavorable associations in COAD, OV, UVM, GBM and CHOL, but favorable associations in SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for GRIFIN RNA expression.
This table summarizes GRIFIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GRIFIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIFIN shows lower tumor expression in LUSC, LUAD, BLCA and UCEC and higher tumor expression in KIRC and KICH. The KIRC box plot shows higher GRIFIN RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with GRIFIN in patient tissues and cancer cell lines. In patient samples, GRIFIN shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIFIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
